DGX, HUM And AET, 3 Health Services Stocks Pushing The Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 22 points (0.1%) at 17,036 as of Wednesday, Sept. 10, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,316 issues advancing vs. 1,661 declining with 150 unchanged.

The Health Services industry currently is unchanged today versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the industry include UnitedHealth Group ( UNH), down 1.4%, Universal Health Services ( UHS), down 1.0% and WellPoint ( WLP), down 1.0%. Top gainers within the industry include Grifols ( GRFS), up 1.5%, Boston Scientific ( BSX), up 1.1%, Medtronic ( MDT), up 0.9% and Covidien ( COV), up 0.7%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Quest Diagnostics ( DGX) is one of the companies pushing the Health Services industry lower today. As of noon trading, Quest Diagnostics is down $0.87 (-1.4%) to $62.96 on light volume. Thus far, 372,760 shares of Quest Diagnostics exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $62.82-$64.00 after having opened the day at $64.00 as compared to the previous trading day's close of $63.83.

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. Quest Diagnostics has a market cap of $9.3 billion and is part of the health care sector. Shares are up 19.2% year-to-date as of the close of trading on Tuesday. Currently there are 2 analysts that rate Quest Diagnostics a buy, 3 analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Quest Diagnostics as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Quest Diagnostics Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Humana ( HUM) is down $1.40 (-1.1%) to $129.05 on average volume. Thus far, 420,575 shares of Humana exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $128.05-$131.05 after having opened the day at $131.05 as compared to the previous trading day's close of $130.45.

Humana Inc., a health care company, offers a range of insurance products, and health and wellness services that incorporate an integrated approach to lifelong well-being. The company operates in Retail, Employer Group, Healthcare Services, and Other Businesses segments. Humana has a market cap of $20.0 billion and is part of the health care sector. Shares are up 26.4% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Humana a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Humana Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Aetna ( AET) is down $1.17 (-1.4%) to $83.77 on average volume. Thus far, 1.1 million shares of Aetna exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $83.52-$84.82 after having opened the day at $84.59 as compared to the previous trading day's close of $84.94.

Aetna Inc. operates as a diversified health care benefits company in the United States. The company operates in three segments: Health Care, Group Insurance, and Large Case Pensions. Aetna has a market cap of $29.8 billion and is part of the health care sector. Shares are up 23.8% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Aetna a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Aetna as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, attractive valuation levels, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Aetna Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

The Really Big Money Rushes to Super Bowl

The Really Big Money Rushes to Super Bowl

'When I Think of October, I Think of Black Monday' -- Market Recon

'When I Think of October, I Think of Black Monday' -- Market Recon

Cramer: These Sectors Look Bullish (Part III)

Cramer: These Sectors Look Bullish (Part III)

Cramer: There Are Powerful Themes in Several Bull Markets

Cramer: There Are Powerful Themes in Several Bull Markets

Stanley Black & Decker, Quest Diagnostics and 2 More Could Rocket Higher This Spring -- Here's Why

Stanley Black & Decker, Quest Diagnostics and 2 More Could Rocket Higher This Spring -- Here's Why